Objective: Successful disease management is heavily influenced by access to care issues and patient behavior. Screening tests to detect chronic complications are part of diabetes management, and may be influenced by access to care or patient decisions. The objective of this research was to examine how strongly access to care and patient behavior predict screening practices. Research Design and Methods: Information on screening practices, access to care, and diabetes management were identified from the Pittsburgh Epidemiology of Diabetes Complications Study, at two time points 1998-2001 and 2002-2006. Information on access to care and patient behavior identified in 1998-2001 were examined relative to screening practices observed in [2002][2003][2004][2005][2006]. Results: Access to care issues positively predicted subsequent screening practices. Specifically, specialist care, number of doctor visits and intensive insulin therapy were all strong predictors for screening use. Receipt of the recommended level of screening tests was also positively associated with the patient behavior of daily blood sugar testing.
The outcome of interest for this investigation is whether or not a screening test to detect diabetes complications or to identify markers for complication risk was received. Screening tests for complications assessed in this evaluation included a dilated eye examination, a urine protein test (by spot urine or timed urine analysis), and a foot examination (visual or monofilament test), while screening tests for complication risk included an HbA1c test, a fasting lipid profile and blood pressure measurement. Patients were asked by questionnaire in 2002-2006 if they had received the above described screening tests at least once over the previous year (twice for HbA1c). Only screening tests that were not part of the EDC study protocol were considered in the context of this evaluation.
Patient behavior and health care access issues were examined as possible factors influencing the use of screening tests. Patient behaviors were defined by the following the selfcare management practices; daily blood sugar testing, changing diet in response to blood sugar levels, changing insulin in response to blood sugar levels, and changing exercise in response to blood sugar levels. Subjects were asked by questionnaire in 1998-2001 to indicate in a yes/no fashion if they participated in any of the aforementioned behaviors.
Health care access variables were defined to include provider-related and system related factors that may facilitate the use of screening tests. Provider-related variables included specialist care, number of doctor visits, and intensive insulin therapy. Individuals were considered to have specialist care if their usual health care provider was a diabetologist, endocrinologist, or nurse, nurse practitioner or physician assistant working with a diabetologist or endocrinologist. (addresses reviewer comment number 2) Subjects with at least 2 doctor visits over a 12 month period were considered to have enhanced access to care and the potential to get screened. Intensive therapy was defined as three insulin injections per day or insulin pump therapy, and was regarded as an access factor because it signals provider adherence to accepted diabetes care practices. Traditional access to care variables based on health system issues was also examined. They included report of barriers to seeing a doctor and the presence of a usual place of care when sick.
It is recognized that health care use, including screening, can be affected by multiple processes. Therefore we also examined several potential confounders to the patient/access and screening test link. These include disease duration, gender, health insurance status, and diabetes complications status. Insurance status was classified as having a full year of coverage or not. Self-reported complications included the presence of proliferative retinopathy or diabetic eye disease requiring laser therapy, myocardial infarction, stroke, diabetes-related renal failure or amputation. Duration of diabetes and gender were identified from the baseline data of the EDC Study and adjusted to reflect the experiences at the time of this report.
Statistical Analysis
Screening was analyzed in two ways in this report: (1) the use of specific, individual screening tests, and (2) the use of multiple screening practices at the optimal level. Optimal screening was defined as at least two HbA1C tests, a dilated eye exam, a urine protein test, a foot exam and a fasting lipid test in the last year. Blood pressure readings were not included as a part of the optimal variable because it is typically a part of routine office visits, and were reported in the overwhelming majority of this population. If individuals were not eligible for a specific screening test (e.g. had end stage renal disease or blindness in both eyes) they were counted as having satisfied that screening criteria for the purposes of this evaluation. The impact of this consideration was small, as only 38 individuals had either end stage renal disease or blindness.
Analyses were conducted using the statistical analysis package, SPSS 13.0. Baseline patient and access to care factors were compared to screening tests at both baseline and at follow-up. The prevalence of screening was tabulated at each time point. Models were created to examine the effect of 1) patient factors, 2) access factors and 3) combined patient and access factors on screening practices. Stepwise logistic regression analysis was conducted with the receipt of a screening test as the outcome variable. Models were adjusted for disease duration, complications status, sex, health insurance status. Variables identified as significant in univariate analyses at the .05 level were included in the model, starting with the variable with the smallest p-value. Variables identified in the literature as being associated with diabetes care, even if not found to be significant at the p≤0.05 level, were also added to examine if these variables influenced the model. When making models combined with access and patient level factors, the most significant variable in univariate analysis at the .05 level was added to the model, regardless of the category the variable fell under (i.e. access or patient level), and model specification continued in a step-wise manner.
Results
There were 393 subjects available for analysis in 1998-2001 and 324 of those subjects had complete information on screening in 2002-2006. Individuals missing follow-up (N=69) data were less likely to report favorable patient self-care behaviors, that consisted of daily blood sugar testing (p=<.001), changing exercise in response to blood sugar levels (p=.019), changing insulin in response to blood sugar testing (p=.042), and changing diet in response to blood sugar levels (p<.001). Individuals missing follow-up data were also less likely to report specialist care (p=.007) and more likely to report a barrier (p<.001) At baseline, the mean age of the cohort was 37.1±7.9 years and the mean disease duration was 26.9±3.9 years. Demographic data at baseline is provided in Table 1 . The majority reported health insurance coverage (94.2%) and a large portion of subjects reported at least one late stage diabetes complication (48%).
Screening Frequency and Characteristics
The prevalence of screening test utilization at baseline and follow-up is reported in Table 2 . Overall, the prevalence of screening increased from baseline to follow-up. The largest improvement was in optimal screening, where the rates doubled between baseline and follow-up. Optimal screening, however, was only reported by 21.9% of respondents at baseline and 44.1% at follow-up. Screening components most frequently missed by subjects lipid testing and HbA1c testing (2 tests) at both baseline and follow-up. (addresses reviewer comment number 3) Daily blood sugar testing, changing exercise in response to blood sugar levels, changing diet in response to blood sugar levels, and changing insulin in response to blood sugar levels were significantly independently associated with receipt of screening tests. At baseline, after adjustments for disease duration, gender, complications, and the presence of health insurance, daily blood sugar testing was positively correlated with all tests. At follow-up, daily blood sugar testing was positively associated with all tests, with the exception of the foot exam. Changing insulin in response to blood sugar levels was associated with fasting lipid testing and receipt of dilated eye exams at baseline, and optimal screening at baseline and follow-up, after adjusting for health insurance, gender, complications, and disease duration. In adjusted regression analysis, changing exercise levels in response to blood sugar levels was positively associated with dilated eye examination at baseline and follow-up, and foot examinations at follow-up. Changing diet in response to blood sugar levels was correlated with dilated eye exam at baseline, adjusted for disease duration, gender, health insurance, and complications.
Multiple regression models were created for access factors and screening tests at baseline and follow-up. At baseline, specialist care, presence of barriers to care, intensive therapy and the number of physician visits were associated with recommended screening tests. Specifically, specialist care (OR=3.5; 95% CI=1.9,6.4), intensive therapy (OR=1.8;95% CI=1.0,3.4)) and the presence of a barrier (OR=.48; 95%CI=.24,.93) were each independently associated with dilated eye examinations. Urine protein screening was associated with number of doctor visits (OR=2.6; 95%CI=1.4, 5.1), specialist care (OR=2.8; 95%CI=1.6, 5.0), intensive therapy (OR 1.9; 95%CI=1.1,3.3), and the presence of a barrier (OR=.52; 95% CI=.27,1.0). Optimal screening and HbA1c testing were both associated with number of doctor visits (OR=9.8; 95% CI=2.3, 42.3 (optimal)), (OR=6.5; 95% CI=3.3, 13.0 (HbA1c)), and specialist care (OR=3.5; 95% CI=1.7, 7.3 (optimal)), (OR=3.6; 95% CI=2.0, 6.6 (HbA1c)). At follow-up, the number of doctor visits and specialist care were independently correlated with urine protein testing (OR=2.3; 95%CI=1.1, 4.6 (number of doctor visits)), (OR=2.0; 95%CI=1.1, 3.7 (specialist)) and HbA1c testing (OR=2.0; 95% CI=1.1, 4.1 (specialist)), (OR=3.4; 95%CI=1.6, 7.1 (number of doctor visits)).
Multiple regression models were created for combined access and patients factors and screening tests at baseline and follow-up. Combined models are presented in Table 3 . (addresses reviewer comment number 1) At baseline, access factors that included the number of doctor visits, barriers to care, specialist care, and the patient level factor of daily blood sugar testing were associated with screening. At follow-up, number of doctor visits and daily blood sugar testing was associated with urine protein screening and optimal screening, and the number of doctor visits and changing insulin in response to blood sugar levels was associated with foot exams.
Discussion
In this study, we examined the relationship between patient-level behavior and access to care, and the receipt of screening tests for diabetes complications. Screening was most often found to be associated with access factors rather than patient behavior issues. Specifically specialist care, the number of doctor visits, the presence of barriers to care, and intensive insulin therapy were all strong predictors for screening. Receipt of recommended tests was also associated with the patient-level factor of daily blood sugar testing.
Several access to care factors were consistently associated with receipt of screening tests, including barriers to care, specialist care, and two annual doctor visits. The reported presence of a barrier to seeing a physician was inversely associated with receipt of screening tests. Lack of access to physician care has been highlighted in the literature as a barrier to receipt of diabetes care in general among patients (17) .
Another finding of our study was the strong correlation between specialist care and the receipt of screening tests. Previous studies have linked specialist care to higher screening rates among diabetes patients and general improvements with diabetes outcomes (18) . Specifically, specialist care has been linked to improvements in blood pressure management, foot ulcers, infection, and screening for complications. These data provide additional evidence of the utility of specialty care (18) (19) (20) . Along with intensive therapy and specialist care, visiting a physician at least two times per year was also positively associated with each screening test evaluated. These data reaffirm the notion that the physician as well as patient care plays an integral role in chronic disease management. For instance, Cook et al found that quarterly physician visits were associated with higher rates of foot examination (21) . Likewise, a recent study conducted by Hensley et al found improvements in intermediate outcomes including blood pressure measurement, lipid levels and HbA1c level correlated with increasing visits to a health care provider (22) . Gary et al also found that patients more likely to have at least four physician visits per year had higher rates of HbA1c testing (23) .
In our study, daily blood sugar testing was the only patient behavior that was consistently associated with screening. Self-monitoring of blood glucose and maintaining appropriate glycemic control is a critical component of diabetes management. It is likely that patients who test their blood sugar daily are in more control of their disease, and thus probably proactive in other areas of management. Day et al found that individuals with better glycemic monitoring and control had higher levels of self-efficacy, emotional adjustment to disease and practical self management skills (24) . Patient characteristics that confer self-monitoring of blood glucose may also lead patients to obtain screening tests. In our data, access level factors appear to have a greater influence on screening than patient level factors. The observed relationship between access factors and screening is plausible because research examining factors related disease management have consistently shown physician and system level variables associated with optimal care. Our findings must be interpreted with a degree of caution, as patient, provider and system factors are not independent, and work together to influence health care (11, 12, 17) . In this study we grouped covariates according to patient or access factor categories that largely characterize the variable, however overlap may still occur. For instance, specialist care and the number of annual doctor visits may be related to patient motivation and health-seeking behavior, in addition to provider characteristics, to influence screening behavior. Likewise, daily blood sugar testing is typically strongly encouraged by health care providers, which may have an impact on a patient's decision to monitor blood sugar daily. Further exploration on the influence of patient motivation on provider type, screening, and disease management is warranted.
There are several limitations to consider when interpreting these findings. First the data were based upon the self-reported experiences of the participants and are subject to recall bias. It was not possible to validate the reported responses for the present study. However, a study conducted by Fowles and colleagues assessed the validity of self-reported disease management data among diabetes patients and found that self-report data is likely to overestimate eye examination and HbA1c testing (25) . Thus, if these findings were applicable to this study, it is possible that our estimates for screening may be high. Additionally, our classification of complications was self-reported and subject to recall error, and thus may not accurately reflect the influence of complications on practices. We compared the self-reported complication data on retinopathy in this study to previous clinical exam findings collected as a part of the EDC study in 1997-1998. The correlation coefficient between the two methods of identifying complications was 0.85, suggesting that the potential bias related to complications may be small. Furthermore, proxy variables were used to describe patient and access factors. We did not have access to administrative databases, pharmacy records, or patient medical records to directly measure level of access or self-care. The indirect assessment of these measures may have contributed to misclassification of patient behavior or level of access.
There is also the potential for selection bias, as all respondents are involved in the longitudinal Pittsburgh Epidemiology of Diabetes Complications study. Health care utilization for study subjects may differ than those of type 1 diabetes patients not participating in the study, and participation in the study may influence health care utilization. The data reported may also reflect survivor bias. Many in the original study cohort have passed away or become too ill to participate. Remaining subjects may have better disease management and higher screening rates which has allowed them to remain in the study.
About 18% of subject surveyed at baseline (1998-2001) did not complete a subsequent follow-up survey (2002) (2003) (2004) (2005) (2006) . Baseline differences between those with follow-up data compared to those without follow-up data were observed. We found that persons missing follow-up data were less likely to report self-care behaviors and specialist care, and more likely to report a barrier to care. This could have influenced our findings, as these patients had poorer self-management practices and access to care, and may also have poorer screening behaviors compared those available for follow-up analysis. Considering the above mentioned limitations, it is possible that screening practices of the type 1 diabetes population may be more accurately reflected in baseline findings rather than follow-up. (addresses reviewer comment number 4) In summary, diabetes management relies on patient level factors as well and access factor that include provider and health care system inputs. Previous research that has examined the combined effect of these factors on general diabetes outcomes and processes of care has consisted of randomized trials, and the majority of these studies were not designed to examine their effect on screening practices. In addition, it has been noted that dissemination of models shown to be effective in randomized trials is often impeded by incompatibility with the health care system and a disconnect with provider practice (26) . This report investigated which factors influence screening in a natural setting, as this likely represents a large portion of patients.
The findings show that access to care factors may play the largest role in utilization of recommended screening tests. Unlike other areas of diabetes management, such as glycemic control, these data suggest that access factors may play a larger role in driving screening than patient-level factors. The findings from this report imply that disease management strategies aimed at increasing screening should have a strong focus on access to care issues that are at the provider or health system factor rather than the patient level. 
